Einzeltreffer — DigiBib

New treatment strategies have improved survival of metastatic colorectal cancer in trials. However, it is not clear whether older patients benefit from these novel therapies, as they are often not included in pivotal trials. Therefore, we investigated treatment patterns and overall survival over time in older patients with metastatic colorectal cancer in a population-based study. We identified 22.192 Dutch patients aged ≥70 years diagnosed with synchronous metastatic colorectal cancer between 2005 and 2020 from the Netherlands Cancer Registry. Changes in treatment over time were assessed with logistic regression models. Survival was assessed by Cox proportional hazard ratios (HR). Results showed that chemotherapy use increased between 2005 and 2015, but declined from 2015 onwards, while more patients received best supportive care. Over time, fewer patients underwent primary tumor resection alone. Although survival of both metastatic colon and rectal cancer improved until 2014, survival of colon cancer decreased from 2014 onwards (HR 1.04, 95% confidence interval [CI] 1.01-1.05), which was seen in all age groups. Survival of metastatic rectal cancer patients remained unchanged from 2014 onwards (HR 1.00, 95% CI 0.98-1.03) in all age groups. In conclusion, treatment patterns of Dutch older patients with synchronous metastatic colorectal cancer rapidly changed from 2005 to 2020, with increasing percentages of patients receiving best supportive care. Survival of metastatic colon cancer decreased from 2014 onwards. The implementation of a colorectal cancer screening program and patient selection might explain why only a subset of older patients seem to benefit from the availability of novel treatment options.

Titel:	Time trends in treatment patterns and survival of older patients with synchronous metastatic colorectal cancer in the Netherlands: A population-based study.
Autor/in / Beteiligte Person:	Baltussen, JC ; de Glas NA ; Liefers, GJ ; Slingerland, M ; Speetjens, FM ; van den Bos F ; Cloos-van Balen, M ; Verschoor, AJ ; Jochems, A ; Spierings, LEAMM ; Holterhues, C ; van Gerven LA ; Mooijaart, SP ; Portielje, JEA ; Derks, MGM
Link:	Full Text Finder (Volltext)
Zeitschrift:	International journal of cancer, Jg. 152 (2023-05-15), Heft 10, S. 2043-2051
Veröffentlichung:	1995- : New York, NY : Wiley-Liss ; <i>Original Publication</i>: 1966-1984 : Genève : International Union Against Cancer, 2023
Medientyp:	academicJournal
ISSN:	1097-0215 (electronic)
DOI:	10.1002/ijc.34422
Schlagwort:	Humans Aged Netherlands Proportional Hazards Models Colonic Neoplasms pathology Colorectal Neoplasms pathology Rectal Neoplasms pathology
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [Int J Cancer] 2023 May 15; Vol. 152 (10), pp. 2043-2051. <i>Date of Electronic Publication: </i>2023 Jan 13. MeSH Terms: Colonic Neoplasms* / pathology ; Colorectal Neoplasms* / pathology ; Rectal Neoplasms* / pathology ; Humans ; Aged ; Netherlands ; Proportional Hazards Models References: Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27:3677-3683. ; Karanicolas PJ, Jarnagin WR, Gonen M, et al. Long-term outcomes following tumor ablation for treatment of bilateral colorectal liver metastases. JAMA Surg. 2013;148:597-601. ; Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342. ; Glimelius B, Stintzing S, Marshall J, Yoshino T, de Gramont A. Metastatic colorectal cancer: advances in the folate-fluoropyrimidine chemotherapy backbone. Cancer Treat Rev. 2021;98:102218. ; Kankerregistratie N. Cijfers over Kanker. Kankerregistratie; 2021. https://iknl.nl/nkr-cijfers. Accessed 03-03-2022. ; Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 2003;21:1383-1389. ; Winther SB, Jorgensen TL, Pfeiffer P, Qvortrup C. Can we predict toxicity and efficacy in older patients with cancer? Older patients with colorectal cancer as an example. ESMO Open. 2016;1:e000021. ; van den Broek CB, Dekker JW, Bastiaannet E, et al. The survival gap between middle-aged and elderly colon cancer patients. Time trends in treatment and survival. Eur J Surg Oncol. 2011;37:904-912. ; Bradley CJ, Yabroff KR, Warren JL, Zeruto C, Chawla N, Lamont EB. Trends in the treatment of metastatic colon and Rectal cancer in elderly patients. Med Care. 2016;54:490-497. ; Sorbye H, Cvancarova M, Qvortrup C, Pfeiffer P, Glimelius B. Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer. Ann Oncol. 2013;24:2354-2360. ; Sineshaw HM, Robbins AS, Jemal A. Disparities in survival improvement for metastatic colorectal cancer by race/ethnicity and age in the United States. Cancer Causes Control. 2014;25:419-423. ; Vermeer NCA, Claassen YHM, Derks MGM, et al. Treatment and survival of patients with colon cancer aged 80 years and older: a EURECCA international comparison. Oncologist. 2018;23:982-990. ; Mitry E, Rollot F, Jooste V, et al. Improvement in survival of metastatic colorectal cancer: are the benefits of clinical trials reproduced in population-based studies? Eur J Cancer. 2013;49:2919-2925. ; Kooyker AI, Toes-Zoutendijk E, Opstal-van Winden AWJ, et al. The second round of the Dutch colorectal cancer screening program: impact of an increased fecal immunochemical test cut-off level on yield of screening. Int J Cancer. 2020;147:1098-1106. ; IKNL. National Monitoring of the Colorectal Cancer Screening Programme in the Netherlands. Netherlands Comprehensive Cancer Organisation; 2021 IKNL website. https://iknl.nl/getmedia/046b1a45-b673-4117-9320-9fd8e1823bd6/Monitor-darmkanker-2021-UK-definitieve-versie.pdf. Accessed 20-11-2022. ; Breekveldt ECH, Lansdorp-Vogelaar I, Toes-Zoutendijk E, et al. Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in The Netherlands: a population-based study. Lancet Gastroenterol Hepatol. 2022;7:60-68. ; Integraal Kankercentrum Nederland. I. I. K. Toelichting beschikbaarheid overlevingsgegevens. IKNL (Integraal Kankercentrum Nederland). https://iknl.nl/nkr/registratie/toelichting-beschikbaarheid-overlevingsgegevens. Accessed 16-02-2022. ; Schouten LJ, Hoppener P, van den Brandt PA, Knottnerus JA, Jager JJ. Completeness of cancer registration in Limburg, the Netherlands. Int J Epidemiol. 1993;22:369-376. ; Statistics Netherlands; 2022. Accessed 10-04-2022. ; Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19:335-351. ; Katalinic A, Eisemann N, Kraywinkel K, Noftz MR, Hubner J. Breast cancer incidence and mortality before and after implementation of the German mammography screening program. Int J Cancer. 2020;147:709-718. ; Kvale R, Myklebust TA, Engholm G, Heinavaara S, Wist E, Moller B. Prostate and breast cancer in four Nordic countries: a comparison of incidence and mortality trends across countries and age groups 1975-2013. Int J Cancer. 2017;141:2228-2242. ; Guiriguet C, Pera G, Castells A, et al. Impact of comorbid conditions on participation in an organised colorectal cancer screening programme: a cross-sectional study. BMC Cancer. 2017;17:524. ; van der Meulen MP, Toes-Zoutendijk E, Spaander MCW, et al. Socioeconomic differences in participation and diagnostic yield within the Dutch national colorectal cancer screening programme with faecal immunochemical testing. PLoS One. 2022;17:e0264067. ; Krul MF, Elferink MAG, Kok NFM, et al. Initial impact of national CRC screening on incidence and advanced colorectal cancer. Clin Gastroenterol Hepatol. 2022;22:S1542-3565. ; RIVM. Trends in het aantal CT-onderzoeken. Het aantal CT-onderzoeken voor de jaren 1991 tot en met 2019; Rijksinstituut voor Volksgezondheid en Milieu (RIVM); 2021. https://www.rivm.nl/medische-stralingstoepassingen/trends-en-stand-van-zaken/diagnostiek/computer-tomografie/trends-in-aantal-ct-onderzoeken. Accessed 22-06-2022. ; van Leersum NJ, Janssen-Heijnen ML, Wouters MW, et al. Increasing prevalence of comorbidity in patients with colorectal cancer in the south of the Netherlands 1995-2010. Int J Cancer. 2013;132:2157-2163. ; Folprecht G, Cunningham D, Ross P, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol. 2004;15:1330-1338. ; Razenberg LG, van Erning FN, Pruijt HF, et al. The impact of age on first-line systemic therapy in patients with metachronous metastases from colorectal cancer. J Geriatr Oncol. 2017;8:37-43. ; Venderbosch S, Doornebal J, Teerenstra S, Lemmens W, Punt CJ, Koopman M. Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG). Acta Oncol. 2012;51:831-839. ; Hamers PAH, Elferink MAG, Stellato RK, et al. Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real-life data. Int J Cancer. 2021;148:296-306. ; Scheer MG, Sloots CE, van der Wilt GJ, Ruers TJ. Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases. Ann Oncol. 2008;19:1829-1835. ; Poultsides GA, Servais EL, Saltz LB, et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol. 2009;27:3379-3384. ; Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol. 2012;23:2479-2516. ; Jarnagin WR, Gonen M, Fong Y, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg. 2002;236:397-406. discussion 406-397. ; LUMC. Landelijke richtlijn met regionale toevoegingen. Coloncarcinoom. 2.0 ed. Landelijke Werkgroup Gastro Intestinale Tumoren; 2008. www.lumc.nl. ; Mekenkamp LJ, Koopman M, Teerenstra S, et al. Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases. Br J Cancer. 2010;103:159-164. ; Bakkers C, Lurvink RJ, Rijken A, et al. Treatment strategies and prognosis of patients with synchronous or metachronous colorectal peritoneal metastases: a population-based study. Ann Surg Oncol. 2021;28:9073-9083. ; Seymour MT, Thompson LC, Wasan HS, et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet. 2011;377:1749-1759. ; Winther SB, Liposits G, Skuladottir H, et al. Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2019;4:376-388. ; Decoster L, Kenis C, Naessens B, et al. Integrating geriatric assessment in the first line chemotherapy treatment in older patients with metastatic colorectal cancer: results of a prospective observational cohort study (AVAPLUS). J Geriatr Oncol. 2018;9:93-101. ; Mohile SG, Mohamed MR, Xu H, et al. Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study. Lancet. 2021;398:1894-1904. Contributed Indexing: Keywords: metastatic colorectal cancer; older adults; population-based study; survival; treatment patterns Entry Date(s): Date Created: 20230109 Date Completed: 20230314 Latest Revision: 20230320 Update Code: 20231215

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Time trends in treatment patterns and survival of older patients with synchronous metastatic colorectal cancer in the Netherlands: A population-based study.